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Br ief Definit ive Repor t
Despite advancements in our understanding of 
innate and adaptive immunity, applying this 
knowledge to the treatment of sepsis has proven 
difficult. Sepsis causes a dramatic systemic in-
flammatory response syndrome (SIRS) but is 
also capable of causing dysfunction in both the 
innate and adaptive branches of the immune sys-
tem (Bone, 1996; Döcke et al., 1997; Hotchkiss 
and Karl, 2003). In patients receiving appropri-
ate resuscitation, the early systemic SIRS phase 
is rarely lethal, and patients increasingly suc-
cumb to secondary infections and organ failure 
during a prolonged period of immunosuppres-
sion and failure in host defense (Bone, 1996; 
Hotchkiss and Karl, 2003). Understanding both 
phases of human sepsis requires the applica-
tion of appropriate animal models that can pro-
duce a SIRS response that can be overcome 
to allow the study of host defense during the 
more prolonged phases in sepsis. To this end, we 
use the cecal ligation and puncture (CLP) 
model of sepsis that creates a significant but not 
overwhelming SIRS response, allowing us to 
dissect factors that control host defense during 
prolonged sepsis (Scumpia et al., 2006, 2007; 
Delano et al., 2007).
Many factors modulate innate and adaptive 
immune responses and link the two branches 
of immunity during infection. Type I IFNs, 
including IFN-, IFN-, and IFN-, are ubiq-
uitious cytokines originally shown to inhibit 
viral infection (Lindenmann et al., 1957; Isaacs 
and Burke, 1959). Recently, type I IFNs were 
shown to act downstream of Toll-like receptor 
signaling (Uematsu and Akira, 2007) to induce 
a specific gene activation signature, including 
induction of chemokines such as CXCL10 and 
MCP-5 (Toshchakov et al., 2002), and anti-
microbial/antiviral response genes (Sadler and 
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Type I interferon (IFN) / is critical for host defense. During endotoxicosis or highly 
lethal bacterial infections where systemic inflammation predominates, mice deficient in 
IFN-/ receptor (IFNAR) display decreased systemic inflammation and improved out-
come. However, human sepsis mortality often occurs during a prolonged period of immuno-
suppression and not from exaggerated inflammation. We used a low lethality cecal 
ligation and puncture (CLP) model of sepsis to determine the role of type I IFNs in host 
defense during sepsis. Despite increased endotoxin resistance, IFNAR/ and chimeric mice 
lacking IFNAR in hematopoietic cells display increased mortality to CLP. This was not 
associated with an altered early systemic inflammatory response, except for decreased 
CXCL10 production. IFNAR/ mice display persistently elevated peritoneal bacterial 
counts compared with wild-type mice, reduced peritoneal neutrophil recruitment, and 
recruitment of neutrophils with poor phagocytic function despite normal to enhanced 
adaptive immune function during sepsis. Importantly, CXCL10 treatment of IFNAR/ mice 
improves survival and decreases peritoneal bacterial loads, and CXCL10 increases mouse 
and human neutrophil phagocytosis. Using a low lethality sepsis model, we identify a 
critical role of type I IFN–dependent CXCL10 in host defense during polymicrobial sepsis 
by increasing neutrophil recruitment and function.
© 2010 Kelly-Scumpia et al. This article is distributed under the terms of an 
Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six 
months after the publication date (see http://www.jem.org/misc/terms.shtml). 
After six months it is available under a Creative Commons License (Attribution–
Noncommercial–Share Alike 3.0 Unported license, as described at http://creative-
commons.org/licenses/by-nc-sa/3.0/).
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(Mahieu et al., 2006; Weighardt et al., 2006; Huys et al., 
2009), which can be augmented by type I IFN, may not be 
playing as large a role in our model.
Type I IFN signaling does not play a major role  
in CLP-induced systemic inflammation
To investigate whether type I IFN had an effect on systemic 
cytokine responses in our CLP model, Luminex multiplex 
analysis was performed on plasma samples over the early 
course of CLP. Type I IFN signaling did not play a major role 
in the global cytokine or chemokine response after CLP. 
Preliminary data shows that plasma levels of most cytokines 
measured, including TNF-, IL-6, IL-1, and IL-10 were 
comparable between SEV129 and IFNAR/ mice (data not 
depicted for IL-10; Fig. 2 A). In fact, IFNAR/ mice pro-
duced significantly higher levels of KC, a chemokine highly 
induced during bacterial infection, 6 h after CLP than their 
wild-type counterparts (Fig. 2 A). The only cytokine signifi-
cantly decreased in IFNAR/ mice was the IFN-inducible 
chemokine CXCL10, which was decreased by >60% when 
compared with wild-type levels (IP-10; Fig. 2 A).
It is important to note that the early inflammatory re-
sponse in lethal endotoxicosis and the CASP model is often 
several magnitudes higher than seen in human sepsis, as deter-
mined by plasma cytokine concentrations. In mouse endo-
toxicosis, for example, serum TNF and IL-6 concentrations 
can often reach the nanogram and microgram per milliliter 
levels (Eskandari et al., 1992), which are concentrations often 
three logs higher than those seen in critically ill humans (Rogy 
et al., 1994). During CASP peritonitis, a large bacterial load is 
Williams, 2008). Type I IFNs also serve as a link between the 
innate and adaptive immune systems (Hoebe and Beutler, 2004), 
participating in autoimmunity (Blanco et al., 2001) and viral 
(Müller et al., 1994) and bacterial infection (O’Connell et al., 
2004; Mancuso et al., 2007). Their functions in severe bacte-
rial infection remain controversial, as signaling through the 
type I IFN pathway has detrimental consequences in certain 
bacterial infections (O’Connell et al., 2004; Martin et al., 
2009) but protective effects in others (Mancuso et al., 2007). 
Importantly, in response to severe endotoxicosis or a highly 
inflammatory model of bacterial peritonitis, colon ascendens 
stent peritonitis (CASP; Maier et al., 2004), absence of the 
receptor for type I IFN (IFN-/ receptor [IFNAR]; Müller 
et al., 1994) was shown to be protective by decreasing the 
systemic hyperinflammation associated with these two mod-
els (Mahieu et al., 2006; Weighardt et al., 2006).
In this report, we dissected the effects of type I IFN sig-
naling on host immunity to a model of polymicrobial sepsis that 
more closely approximates the magnitude and mortality seen 
in human disease. We find that IFNAR/ mice are more 
sensitive to CLP mortality, particularly at later time points. 
We attribute this increased sensitivity to a failure in hemato-
poietic cells, particularly neutrophils, to clear the infection, 
and not to an exaggerated inflammatory response. We dem-
onstrate that when the SIRS response does not predominate, 
type I IFN is required for host defense in sepsis, and that im-
paired induction of the IFN-inducible CXCL10 is at least in 
part responsible for this protection.
RESULTS AND DISCUSSION
Deficiency of type I IFN worsens survival to CLP peritonitis 
but improves survival to endotoxicosis
While investigating whether type I IFN participates in the adap-
tive immune suppression that occurs during sepsis (Scumpia 
et al., 2006; Scumpia et al., 2007), we used our low lethality 
model of CLP that consistently causes 10–20% mortality. To 
our surprise, we observed that beginning 2–3 d after sepsis 
induction, IFNAR/ mice began to die, whereas control 
SEV129 mice continued to survive. By 7 d after CLP, only 45% 
of IFNAR/ mice were alive compared with 95% of the 
wild-type SEV129 mice (Fig. 1 A).
Because previous reports found that the absence of type I 
IFN signaling improves survival to endotoxin- or TNF-induced 
severe shock (Mahieu et al., 2006; Huys et al., 2009), and 
improves outcome in the CASP model of severe bacterial 
peritonitis (Weighardt et al., 2006), we injected wild-type 
SEV129 and IFNAR/ mice with a lethal dose of bacterial 
LPS (500 µg/kg or 10 mg/kg of body weight). Unlike in 
CLP-induced sepsis, in a single pilot experiment, IFNAR/ 
mice were highly resistant to endotoxin-induced mortality, 
confirming previous reports that type I IFN can participate in 
systemic inflammation (IFNAR/ mortality of 8% vs. SEV129 
mortality of 83%; P = 0.0006; Fig. 1 B).
Together with delayed mortality in the low lethality CLP 
model, these data suggest that an exaggerated systemic inflam-
matory response present in highly inflammatory models 
Figure 1. Type I IFN deficiency worsens CLP but not endotoxicosis 
survival. (A) SEV129 and IFNAR/ mice underwent CLP surgery with a 
27-gauge needle, and survival was monitored. The figure is the combina-
tion of two separate experiments with similar results (n = 24 per group; 
*, P = 0.0002 using Fisher’s exact test). (B) SEV129 and IFNAR/ mice were 
given an i.p. injection of 500 µg E. coli O111:B4 LPS, and survival was 
monitored for 7 d. The experiment was performed once (n = 12 per group; 
*, P = 0.0006 using Fisher’s exact test).
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after CLP, IFNAR/ mice displayed decreased bacterial 
loads in the peritoneum compared with wild-type SEV129 
animals, although this difference was not significant (Fig. 2 B). 
At 48 and 96 h after CLP, IFNAR/ mice displayed a sig-
nificant increase in bacterial load compared with the wild-
type SEV129 animals (P < 0.05 at both time points; Fig. 2 B). 
IFNAR/ mice failed to clear persistent infection, suggest-
ing a defect in host defense that may explain the increased 
mortality in IFNAR/ mice. It is important to note that 
the failure of mice to clear bacteria at later time points may 
reflect the mouse model of sepsis chosen and does not fully 
recapitulate human sepsis, where high doses of antibiotics are 
frequently used.
Type I IFN signaling in the hematopoietic system is needed 
for survival to CLP
Because functioning leukocytes are critical to host defense 
and type I IFNs are pleiotropic cytokines that affect how all 
cells respond to infection, we next examined whether type 
I IFN signaling in the hematopoietic system was required 
for sepsis survival. Chimeras were created to test the radio-
sensitive hematopoietic and the radioresistant parenchymal 
systems. In brief, either SEV129 or IFNAR/ mice were 
lethally irradiated and reconstituted with BM from either 
SEV129 or IFNAR/ mice, creating (a) wild-type mice 
reconstituted with wild-type BM, (b) wild-type mice with 
a hematopoietic system that lacked type I IFN signaling, or 
(c) mice lacking IFN expression in parenchymal cells but 
possessing intact type I IFN signaling in their hematopoietic 
cells. Complete chimerism was confirmed using an antibody 
to the IFNAR1 receptor in circulating peripheral blood leu-
kocytes 14 d after reconstitution (Fig. S1).
Using these chimeras, we find that mice with defective 
type I IFN signaling in their hematopoietic system demon-
strate a 40% increase in mortality when compared with the 
wild-type mice reconstituted with a wild-type hematopoietic 
system (P = 0.006; Fig. 3). Mice that possessed an IFNAR/ 
parenchymal system (IFNAR/ mice) but were reconstituted 
with a normal hematopoietic system demonstrate a <15% de-
crease in survival compared with wild-type reconstituted mice 
(n = 26 mice; P = 0.55; not depicted), indicating the impor-
tance of type I IFN signaling within the hematopoietic system 
in host defense during septic peritonitis.
Both neutrophil recruitment and function require  
intact type I IFN signaling
Because phagocytes are the primary mediators of bacterial 
clearance during septic peritonitis, we investigated whether 
type I IFN modulates neutrophil and macrophage responses. 
At various time points after CLP, we examined neutrophil 
and macrophage counts as well as phagocytic function within 
the peritoneal cavity. As expected, CLP induces peritoneal 
neutrophil influx starting as early as 12 h after CLP in wild-
type and IFNAR/ mice. At this early time point, we find 
a small and insignificant decrease in the total number of 
Gr-1highCD11b+ neutrophils of IFNAR/ mice when 
continuously released into the peritoneum, resulting in a large 
initial inflammatory response (Maier et al., 2004). Similar to 
endotoxin shock, the absence of type I IFN decreases the 
magnitude of the systemic inflammatory response and is pro-
tective in this model (Weighardt et al., 2006). When mice are 
given a large bacterial burden, the presence of type I IFN 
propagates inflammation and worsens outcome (Martin et al., 
2009). Alternatively, when mice are infected with smaller 
doses of bacteria causing a smaller inflammatory response, the 
presence of type I IFN appears to be protective by promoting 
bacterial clearance, although the mechanism has not been 
fully explored (Mancuso et al., 2007).
IFNAR/ mice have decreased peritoneal bacterial 
clearance compared with SEV129 mice
Because the early systemic inflammatory response did not 
seem to participate in the increased mortality in IFNAR/ 
mice, we next examined the effect of type I IFN on bacte-
rial clearance. At various time points after CLP, bacterial 
content in the peritoneal lavage fluid was quantified. At 12 h 
Figure 2. Type I IFN signaling does not play a role in inflammation 
associated with CLP. (A) SEV129 and IFNAR/ mice underwent CLP 
surgery and were sacrificed at 0, 6, and 12 h after surgery. Serum cytokine 
levels from peripheral blood were determined by MILLIPLEX MAP Mouse 
Cytokine/Chemokine–Premixed 22 Plex kits. Select cytokines in this figure 
include TNF, KC, IL-6, IL-1, and IP-10. Each time point was performed 
once (n = 3 per group per time point; *, P < 0.05 using the Student’s  
t test). Error bars indicate SD. (B) SEV129 and IFNAR/mice underwent CLP 
surgery and were sacrificed at 12, 48, and 96 h after surgery. Bacteremia 
was determined from peritoneal lavage fluid plated on sheep blood agar. 
Each point represents CFUs from one mouse. The experiment was per-
formed three times (n = 3 per group; P < 0.05 using the Student’s t test). 
Horizontal bars indicate means.
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Enhanced adaptive immune responses  
in septic IFNAR/ mice
We next determined whether type I IFN participates in 
adaptive immune suppression during sepsis. As expected, 
septic wild-type mice displayed impaired antibody production 
(IgM and IgG2a) after immunization with a T cell–dependent 
antigen, NP-KLH. To our surprise, sham-treated IFNAR/ 
mice displayed severely impaired responses when compared 
with wild-type sham mice, but septic IFNAR/ mice dis-
play similar IgM production and enhanced NP-specific IgG2a 
production compared with sham IFNAR/ mice (Fig. S2). 
This suggests that the increased mortality in IFNAR/ mice 
during sepsis cannot be easily explained by changes in adap-
tive immunity.
compared with wild-type mice (Fig. 4 A). By 48 h, however, 
neutrophil recruitment is significantly less in IFNAR/ 
mice, indicating that type I IFN signaling is required for early 
neutrophil recruitment after CLP (Fig. 4 A). Consistent with 
increasing bacterial loads in the peritoneum at 96 h after 
CLP, IFNAR/ mice actually have an increased number of 
peritoneal neutrophils, whereas the peritoneal neutrophil 
counts in wild-type mice continue to decline with their con-
tinued clearance of bacteria (Fig. 4 A). These data suggest 
that IFNAR/ neutrophils are failing to clear the bacteria at 
this late time point.
We next examined whether macrophage recruitment was 
altered by deficient type I IFN signaling. We found that 12 h 
after CLP, there is a modest recruitment of macrophages to 
the peritoneum, but this is 10-fold lower than the recruit-
ment of neutrophils (Fig. 4 B). Consistent with macrophages 
participating in later phases of inflammation, 48 h after CLP, 
macrophage recruitment increases and this continues through 
96 h after CLP (Fig. 4 B). Although we found a trend to 
decreased macrophage recruitment in IFNAR/ mice at 
both 48 and 96 h after CLP, these data failed to reach signifi-
cance (Fig. 4 B).
Because phagocytosis is an important function of both 
neutrophils and macrophages, we next examined whether 
type I IFN participates in the phagocytic function of perito-
neal neutrophils by measuring their ability to engulf fluores-
cent beads ex vivo. As expected, neutrophil phagocytic 
function decreases over time after CLP in both wild-type and 
IFNAR/ mice. Interestingly, although the ability to phago-
cytose stabilized at days 2 and 4 in wild-type mice, phagocytic 
function of IFNAR/ mice continued to decline (Fig. 4 C). 
Although phagocytic function in macrophages also declined, 
IFNAR deficiency did not alter macrophage phagocytic 
function (Fig. 4 D). This inability to fully activate neutrophil 
phagocytic function, coupled with the earlier deficiency in 
neutrophil recruitment, likely explains the increased bacterial 
load seen after sepsis in IFNAR/ mice.
Figure 3. Type I IFN signaling in the hematopoietic system is 
needed for survival to CLP. SEV129 mice irradiated and reconstituted 
with BM from SEV129 or IFNAR/ mice underwent CLP surgery with a 
27-gauge needle, and survival was monitored for 12 d. The figure is the 
combination of two separate experiments with similar results (n = 26 
for the SEV129 group and 27 for the IFNAR/ group; *, P = 0.0006 
using Fisher’s exact test).
Figure 4. Neutrophil and macrophage recruitment and phago-
cytic function require intact type I IFN signaling. SEV129 wild-type 
and IFNAR/ mice underwent CLP surgery and were sacrificed at 12, 
48, and 96 h after surgery. Peritoneal cells were stained extracellularly 
for flow cytometry. (A) Total neutrophil counts were determined by gat-
ing on Gr1+CD11b+ cells. (B) The total number of macrophages was de-
termined by gating on CD11b+F4/80+ cells. The dashed lines indicate the 
total number of neutrophils (A) or macrophages (B) found in sham ani-
mals. (C and D) 100,000 cells were incubated with FITC beads for 30 min 
at 37°C. Cells were washed two times with PBS and stained extracellu-
larly for flow cytometry. (C) Cells were first gated on neutrophils 
(Gr1+CD11b+ cells), and then FITC+ cells were considered phagocytic.  
(D) Cells were first gated on macrophages (CD11b+F4/80+ cells), and then 
FITC+ cells were considered phagocytic. The dashed lines indicate sham 
phagocytic levels. *, P < 0.05 using the Student’s t test. Error bars indi-
cate SD. The data shown for all panels were obtained with 10 mice per 
group performed over three independent experiments.
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Treatment of human neutrophils with CXCL10  
improves phagocytosis
Septic adult peripheral blood neutrophils demonstrate re-
duced phagocytic activity during sepsis (Kaufmann et al., 
2006; Danikas et al., 2008; Taneja et al., 2008). Although no 
human studies have examined whether type I IFN is in-
creased in sepsis, CXCL10 was shown to be an early marker 
of sepsis in neonates and adults. Whether CXCL10 mediates 
neutrophil phagocytosis in humans, or whether levels during 
sepsis are sufficient or sustained long enough to mediate ade-
quate neutrophil recruitment and phagocytic activity is un-
known. In this report, we find that although human blood 
neutrophils (CD66b+CD16hi cells) have a low phagocytic ac-
tivity, treatment for 4 h with CXCL10 doubles their phago-
cytic ability (Fig. 6 A). Furthermore, treatment with CXCL10 
for 2 h improves LPS-mediated neutrophil phagocytosis 
(P < 0.001 using one-way ANOVA; Fig. 6 B). These data sug-
gest that CXCL10 treatment may improve neutrophil phago-
cytosis in sepsis.
In summary, our study identifies type I IFN responsive-
ness in the hematopoietic system as a protective factor in bac-
terial sepsis. We demonstrate a role of type I IFN in neutrophil 
recruitment and phagocytic function during the later stages 
of bacterial peritonitis. Without type I IFN–dependent neu-
trophil recruitment and activation, mice fail to clear bacteria, 
resulting in a persistently elevated bacterial burden. Previ-
ously, CXCL10 blockade was shown to worsen outcome to 
sepsis (Ness et al., 2003). We further demonstrate that maxi-
mal induction of CXCL10 during sepsis requires type I IFN, 
and administration of CXCL10 alone restores neutrophil re-
cruitment and improves bacterial clearance in IFNAR/ mice. 
In addition, treatment of human neutrophils with CXCL10 
improves their phagocytic ability. These data provide evi-
dence for a dual role of type I IFN in bacterial host defense, 
Administration of CXCL10 improves outcome  
by decreasing bacteremia in IFNAR/ mice
Type I IFN activates many host defense pathways that par-
ticipate in host protection during sepsis. We found that plasma 
CXCL10 concentrations were decreased in IFNAR/ mice. 
CXCL10 is a potent neutrophil chemoattractant (Zeng 
et al., 2005) that has been deemed an important host de-
fense in bacterial peritonitis in mice (Ness et al., 2003), and 
is known to increase in human neonatal sepsis (Ng et al., 
2006) and adults (Olszyna et al., 1999). We examined 
whether replacement of CXCL10 may improve survival in 
IFNAR/ mice.
Indeed, treatment of IFNAR/ mice with CXCL10 6 
and 72 h after CLP improved survival compared with 
IFNAR/ mice treated with vehicle control (P = 0.01 
using Fisher’s exact test; Fig. 5 A), and brought survival 
close to wild-type levels (54% in SEV mice vs. 50% in IF-
NAR/ mice with CXCL10). Similarly, a single dose of 
CXCL10 6 h after CLP caused an increase in bacterial 
peritoneal clearance, resulting in decreased peritoneal bac-
terial counts 48 h after CLP (P = 0.01 using the Mann-
Whitney U test; Fig. 5 B).
CXCL10 administration increases peritoneal neutrophil 
function and recruitment in wild-type and IFNAR/ mice
We next determined whether CXCL10 treatment improved 
bacterial clearance in wild-type and IFNAR/ mice by af-
fecting neutrophil recruitment and phagocytic function. We 
find that in both wild-type and IFNAR/ mice, a single 
dose of CXCL10 increases phagocytic neutrophil recruitment 
18 h after treatment (P = 0.001 using one-way analysis of 
variance [ANOVA]; Fig. 5 C). There was a trend toward in-
creased recruitment of neutrophils in IFNAR/ mice, but 
this did not achieve significance.
Figure 5. CXCL10 improves outcome by decreasing bacteremia in IFNAR/ mice. (A) SEV129 wild-type mice (n = 10), IFNAR/ mice (n = 11), or 
IFNAR/ mice with 100 ng CXCL10 6 h and on day 3 after CLP (n = 11). Survival was monitored for 7 d. There was a 50% survival advantage in SEV129 
wild-type compared with IFNAR/ mice, and a 54% survival advantage in IFNAR/ + CXCL10 compared with IFNAR/ mice. *, P = 0.01 using Fisher’s 
exact test. Data are from a single experiment with 10 mice in the SEV129 group and 11 mice in the IFNAR/ and IFNAR/ + CXCL10 groups. Two inde-
pendent survival experiments were performed with consistent results. (B) IFNAR/ mice underwent CLP surgery, and 6 h after surgery mice were injected 
with PBS or 100 ng of recombinant IP-10. Mice were sacrificed 48 h after CLP, and bacteremia was determined from dilutions of peritoneal lavage fluid 
obtained aseptically. Each point represents CFUs from one mouse. P < 0.05 using the Student’s t test. Horizontal bars indicate means. The figure repre-
sents data from two independent experiments using four mice per group with similar results. (C) SEV129 wild-type and IFNAR/ mice were injected with 
100 ng CXCL10. Peritoneal cells were harvested 18 h later and were examined by flow cytometry for phagocytic neutrophils (Gr1+CD11b+ cells containing 
FITC+ latex beads). *, P = 0.001 using one-way ANOVA; *, P < 0.05 using the Tukey post hoc analysis. Error bars indicate SD. The figure represents data 
from three independent experiments using at least four mice per group with similar results.
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pleiotropic molecules such as complement C5a receptors and 
HMGB1 can also show immunomodulatory effects on host 
defense and inflammation depending on the severity of the 
septic insult (Rittirsch et al., 2008). These studies, in concor-
dance with our own, highlight the plasticity of immunomod-
ulatory signaling cascades and their ability to participate in either 
detrimental systemic inflammatory cascades or protective host 
defense responses depending on the bacterial burden.
MATERIALS AND METHODS
Human cell-culture studies. The collection of peripheral venous blood 
from unidentified human volunteers was approved by the Institutional 
Review Board of the University of Florida. No identifying personal infor-
mation was collected, and all volunteers signed informed consent.
Mice. All experiments were approved by the Institutional Animal Care and 
Use Committee at the University of Florida College of Medicine. IFN-
/R/A129 mice on the 129S6/SvEv background (H-2b; IFNAR/) and 
wild-type SEV129 mice were purchased from B&K Universal. All mice 
were maintained at the University of Florida College of Medicine.
Endotoxicosis and CLP. For induction of endotoxicosis, mice were in-
jected with 500 µg LPS isolated from Escherichia coli strain O111:B4 (Sigma-
Aldrich) i.p. For induction of polymicrobial sepsis, mice underwent CLP or 
a sham procedure, as previously described (Delano et al., 2007), to obtain a 
mortality of 10–20% in control mice by 10 d. In brief, a laparotomy was 
performed, the cecum was isolated, and 0.5 cm of cecum was ligated be-
low the ileocecal valve and punctured through and through with a 27-gauge 
needle. Sham operation was performed by isolating the cecum without liga-
tion or puncture.
Isolation of human leukocytes. Leukocytes were harvested using a His-
topaque 1119 density gradient. In brief, whole blood was gently added to a 
layer of Histopaque 1119 (Sigma-Aldrich) and centrifuged at 700 g for 30 min 
at room temperature. A clear opaque layer of cells was visible within the 
gradient. This layer containing mixed leukocytes was harvested and washed 
with PBS. Cells were counted using a hemocytometer and plated in round-
bottom 96-well plates in RPMI 1640 containing 10% FBS (Cellgro), and 
then stimulated ex vivo with the recombinant CXCL10. We recognize that 
the responses to CXCL10 treatment reflect both the direct effects of the cyto-
kine on the neutrophil and macrophage populations, as well as effects sec-
ondary to CXC10 on other contained leukocyte populations.
Administration of CXCL10 (IP-10). For in vivo chemokine treatment, 
each mouse was injected i.p. with 100 ng of mouse recombinant IP-10 
(R&D Systems) or PBS 6 h after surgery, and if experiments lasted longer 
than 3 d, again on day 3 (Vasquez and Soong, 2006). For ex vivo studies, re-
combinant human CXCL10 (R&D Systems) was reconstituted, as suggested 
by the manufacturer, in sterile PBS, and human leukocytes were treated 
with 100 ng CXCL10 for 2 h followed by stimulation with 1 µg/ml LPS. In 
some cases, the leukocytes were stimulated with CXCL10 for 4 h followed 
by a phagocytosis assay.
Phagocytosis assay. 105 cells were incubated with 108 yellow-green fluores-
cent polystyrene microspheres (FluoSpheres; Invitrogen) for 30 min at 37°. Cells 
were then washed and stained for additional markers (see Flow cytometry).
Flow cytometry. Immediately after mice were euthanized, 10 ml of physi-
ological saline was injected into the peritoneal cavity and was lavaged repeat-
edly. Cells were washed in PBS, pelleted, and subsequently stained for flow 
cytometry. Mouse peritoneal cells were characterized using anti-Gr1–PE, 
anti-CD11b–FITC, and F4/80 allophycocyanin–Alexa Fluor 750. Human 
neutrophils were characterized using anti-CD66b–biotin (R&D Systems), 
contributing to either detrimental inflammation when sys-
temic inflammation predominates or neutrophil-mediated 
host defense when optimal bacterial clearance is necessary for 
host survival.
Type I IFN is required for survival in the much less lethal 
model of polymicrobial sepsis. A similar difference between 
these models was also found in mice deficient in the Toll-like 
receptor adaptor protein MyD88. Although MyD88 defi-
ciency was protective against CASP peritonitis (Weighardt 
et al., 2002), MyD88 deficiency was found to worsen out-
come to CLP-induced peritonitis, presumably by decreasing 
host defense factors, resulting in increased bacterial dissemi-
nation (Peck-Palmer et al., 2008). Similarly, in a neonatal 
group B streptococcus sepsis model, MyD88/ neonates 
succumbed to a low-dose inoculum of bacteria, whereas 
wild-type mice survived, and the opposite was true of a high-
dose inoculum of bacteria (Mancuso et al., 2004). Other 
Figure 6. CXCL10 treatment improves human neutrophil phago-
cytic function in vitro. Whole-blood leukocytes were collected using 
Histopaque 1119. 105 unstimulated cells, cells treated with 100 ng CXCL10 
for 4 or 2 h followed by an 18-h stimulation with 1 µg/ml LPS, or cells 
stimulated with LPS alone for 18 h were plated in round-bottom 96-well 
plates. FITC beads were added and cells were incubated at 37°C for 30 min. 
Cells were washed and stained for neutrophil markers (CD66b+CD16hi).  
(A) Representative histograms of the percentage of phagocytic neutrophils 
from unstimulated (top) or CXCL10 treatment for 4 h (bottom). (B) Graphi-
cal analysis of the percentage of phagocytic neutrophils from one healthy 
control (P = 0.019 using the Student’s t test). (C) Representative histo-
grams of the percentage of phagocytic neutrophils from unstimulated 
(top), LPS-stimulated (middle), and CXCL10-treated + LPS-treated leuko-
cytes (bottom). (D) Graph of the percentage of phagocytic neutrophils 
from one healthy control (P < 0.001 using one-way ANOVA). For all panels, 
treatment was performed in triplicate and the experiment was performed 
on three healthy controls with similar results. Error bars indicate SD.
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followed by a streptavidin–PerCP-Cy5.5 conjugation and anti-CD16–PE. 
Cells were counted and flow cytometry was performed using antibodies 
purchased from BD unless otherwise stated. Samples were acquired and ana-
lyzed on a flow cytometer (LSR II; BD). At least 104 live (SYTOX Blue; 
Invitrogen) cells were analyzed.
Chimeras. SEV129 or IFNAR/ mice were treated with 1,000 rads of  ra-
diation. Mice were reconstituted with BM from either SEV129 or IFNAR/ 
mice 24 h later. Mice were placed on antibiotic water 1 wk before irradiation 
and were maintained on antibiotic water for 6 wk after reconstitution. Chime-
ras were verified by staining blood collected 14 d after reconstitution with an 
antibody to the extracellular domain of the IFNAR1 subunit of IFNAR (Bio-
Legend). Survival studies were performed 7–8 wk after reconstitution.
Determination of bacterial load. Peritoneal bacterial counts were deter-
mined by culturing 100 µl of serially diluted peritoneal washings on sheep’s 
blood agar plates (Thermo Fisher Scientific) at 37°C in 5% CO2. Plates were 
counted after 24 h of culture.
Multiplex cytokine analysis. Assessments of cytokine profiles from the 
proliferation assay were performed using a commercially available multi-
plexed kit (MILLIPLEX MAP Mouse Cytokine/Chemokine–Premixed 22 
Plex; Millipore). Simultaneous measurement of 22 cytokines/chemokines 
was performed. All assays were performed according to the manufacturer’s 
protocols. Samples were diluted 1:1 in the assay buffer provided with the kit, 
and at least two replicate wells were plated per sample. Cytokine concentra-
tions were determined using BeadView software (Millipore).
Statistics. Differences in survival were determined by Fisher’s exact test. 
Continuous variables were first tested for normality and equality of vari-
ances. Differences among groups were evaluated by the Student’s t test or 
one-way ANOVA with the Tukey post hoc analysis where stated. Signifi-
cance was determined at the 95% confidence level.
Online supplemental material. Fig. S1 shows verification of IFNAR//
SEV129 chimeras. Fig. S2 depicts adaptive immune antibody responses to 
NP-KLH immunization. Online supplemental material is available at http://
www.jem.org/cgi/content/full/jem.20091959/DC1.
This work was supported in part by grants R01 GM-40586-21 and R01 GM-81923-
02 awarded by the National Institute of General Medical Sciences (NIGMS), United 
States Public Health Service. K.M. Kelly-Scumpia, M.J. Delano, and A.G. Cuenca were 
supported in part by grant T32 GM-08721-11, a postgraduate training grant in 
burns and trauma, awarded by the NIGMS.
The authors have no conflicting financial interests.
Submitted: 8 September 2009
Accepted: 24 December 2009
REFERENCES
Blanco, P., A.K. Palucka, M. Gill, V. Pascual, and J. Banchereau. 2001. 
Induction of dendritic cell differentiation by IFN-alpha in systemic lupus 
erythematosus. Science. 294:1540–1543. doi:10.1126/science.1064890
Bone, R.C. 1996. Sir Isaac Newton, sepsis, SIRS, and CARS. Crit. Care 
Med. 24:1125–1128. doi:10.1097/00003246-199607000-00010
Danikas, D.D., M. Karakantza, G.L. Theodorou, G.C. Sakellaropoulos, 
and C.A. Gogos. 2008. Prognostic value of phagocytic activity of 
neutrophils and monocytes in sepsis. Correlation to CD64 and CD14 
antigen expression. Clin. Exp. Immunol. 154:87–97. doi:10.1111/
j.1365-2249.2008.03737.x
Delano, M.J., P.O. Scumpia, J.S. Weinstein, D. Coco, S. Nagaraj, K.M. 
Kelly-Scumpia, K.A. O’Malley, J.L. Wynn, S. Antonenko, S.Z. Al-Quran, 
et al. 2007. MyD88-dependent expansion of an immature GR-1+ 
CD11b+ population induces T cell suppression and Th2 polarization in 
sepsis. J. Exp. Med. 204:1463–1474. doi:10.1084/jem.20062602
Döcke, W.D., F. Randow, U. Syrbe, D. Krausch, K. Asadullah, P. Reinke, 
H.D. Volk, and W. Kox. 1997. Monocyte deactivation in septic patients: 
326 CXCL10 protects IFNAR/ mice from sepsis | Kelly-Scumpia et al.
Rittirsch, D., M.A. Flierl, B.A. Nadeau, D.E. Day, M. Huber-Lang, C.R. 
Mackay, F.S. Zetoune, N.P. Gerard, K. Cianflone, J. Köhl, et al. 2008. 
Functional roles for C5a receptors in sepsis. Nat. Med. 14:551–557. 
doi:10.1038/nm1753
Rogy, M.A., S.M. Coyle, H.S. Oldenburg, C.S. Rock, P.S. Barie, K.J. Van 
Zee, C.G. Smith, L.L. Moldawer, and S.F. Lowry. 1994. Persistently el-
evated soluble tumor necrosis factor receptor and interleukin-1 receptor 
antagonist levels in critically ill patients. J. Am. Coll. Surg. 178:132–138.
Sadler, A.J., and B.R. Williams. 2008. Interferon-inducible antiviral effec-
tors. Nat. Rev. Immunol. 8:559–568. doi:10.1038/nri2314
Scumpia, P.O., M.J. Delano, K.M. Kelly, K.A. O’Malley, P.A. Efron, P.F. 
McAuliffe, T. Brusko, R. Ungaro, T. Barker, J.L. Wynn, et al. 2006. 
Increased natural CD4+CD25+ regulatory T cells and their suppressor 
activity do not contribute to mortality in murine polymicrobial sepsis. 
J. Immunol. 177:7943–7949.
Scumpia, P.O., M.J. Delano, K.M. Kelly-Scumpia, J.S. Weinstein, J.L. Wynn, 
R.D. Winfield, C. Xia, C.S. Chung, A. Ayala, M.A. Atkinson, et al. 2007. 
Treatment with GITR agonistic antibody corrects adaptive immune dysfunc-
tion in sepsis. Blood. 110:3673–3681. doi:10.1182/blood-2007-04-087171
Taneja, R., A.P. Sharma, M.B. Hallett, G.P. Findlay, and M.R. Morris. 
2008. Immature circulating neutrophils in sepsis have impaired 
phagocytosis and calcium signaling. Shock. 30:618–622. doi:10.1097/ 
SHK.0b013e318173ef9c
Toshchakov, V., B.W. Jones, P.Y. Perera, K. Thomas, M.J. Cody, S. Zhang, B.R. 
Williams, J. Major, T.A. Hamilton, M.J. Fenton, and S.N. Vogel. 2002. 
TLR4, but not TLR2, mediates IFN-beta-induced STAT1alpha/beta-
dependent gene expression in macrophages. Nat. Immunol. 3:392–398. 
doi:10.1038/ni774
Uematsu, S., and S. Akira. 2007. Toll-like receptors and type I interferons.  
J. Biol. Chem. 282:15319–15323. doi:10.1074/jbc.R700009200
Vasquez, R.E., and L. Soong. 2006. CXCL10/gamma interferon-inducible 
protein 10-mediated protection against Leishmania amazonensis infection 
in mice. Infect. Immun. 74:6769–6777. doi:10.1128/IAI.01073-06
Weighardt, H., S. Kaiser-Moore, R.M. Vabulas, C.J. Kirschning, H. 
Wagner, and B. Holzmann. 2002. Cutting edge: myeloid differentia-
tion factor 88 deficiency improves resistance against sepsis caused by 
polymicrobial infection. J. Immunol. 169:2823–2827.
Weighardt, H., S. Kaiser-Moore, S. Schlautkötter, T. Rossmann-Bloeck, U. 
Schleicher, C. Bogdan, and B. Holzmann. 2006. Type I IFN modulates 
host defense and late hyperinflammation in septic peritonitis. J. Immunol. 
177:5623–5630.
Zeng, X., T.A. Moore, M.W. Newstead, J.C. Deng, N.W. Lukacs, and T.J. 
Standiford. 2005. IP-10 mediates selective mononuclear cell accumula-
tion and activation in response to intrapulmonary transgenic expression 
and during adenovirus-induced pulmonary inflammation. J. Interferon 
Cytokine Res. 25:103–112. doi:10.1089/jir.2005.25.103
